Esketamine nasal spray: real world use in the Department of Mental Health of Rimini (Italy)
European Psychiatry June 1, 2026 M. P. Rapagnani, L. Veronesi, F. Sartini
Introduction In treatment-resistant depression, commonly defined as a lack of response to two or more consecutive treatments of antidepressants. Esketamine (the S-enantiomer of ketamine) nasal spray, administered in combination with either a selective serotonin reuptake inhibitor (SSRI) or a serotonine-norepinephrine reuptake inhibitor (SNRI), is the only treatment approved in Europe...